• To compare the performance of two techniques to monitor the clearance of AK lesions (clinical and subclinical) when treated with Aldara 5% cream by comparison of lesion counts. [ Time Frame: 8 weeks after the end of treatment ] [ Designated as safety issue: Yes ]
  

• To obtain histological confirmation of the diagnosis of the lesions demonstrated by biopsy. [ Time Frame: 8 weeks after the end of treatment ] [ Designated as safety issue: Yes ]
  

Each technique will be assessed by comparison of lesion counts (clinical and sub-clinical) revealed by the techniques, at start and end of the study and those demonstrated during treatment. In addition a qualitative assessment of each technique will be made for performance and ease of use.

Inclusion Criteria:

• At least 5 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions
• Free of any significant findings (e.g tattoos) in the potential application site area.
• Willing to discontinue sun-tanning and use of sunbed/sun parlour use
• Willing to stop use of moisturisers, body oils, and over the counter retinol products or products containing alpha or beta hydroxyacids in the treatment or surrounding area.
• Willing ot withhold sunscreen and/or moisturiser use for 24 hours prior to each clinical assessment

Exclusion Criteria:

• Evidence of unstable or uncontrolled clinically significant medical condition.
• Any dermatological disease and or condition in the treatment of the surrounding area that may be exacerbated by treatment with imiquimod.
• Currently participating in another clinical study or have completed another study within an investigational drug within the past 30 days.
• Have active chemical dependency or alcoholism
• Have know allergies to any excipient or study cream
• Have received previous treatment with imiquimod for any indication within the treatment area.
• Known to be affected by porphyria